ChemBioChem,
Journal Year:
2022,
Volume and Issue:
24(3)
Published: Dec. 1, 2022
Abstract
Bioorthogonal
prodrugs
with
both
fast
reaction
kinetics
and
multiple
outputs
are
highly
desirable
but
only
found
sporadically.
Herein,
we
report
a
novel
photoclick‐and‐release
strategy
for
the
co‐activation
of
carbon
monoxide
self‐reporter,
carbonyl
sulfide,
or
sulfonamide
(
k
:
1.4–22.6
M
−1
s
).
Such
was
successfully
applied
in
live
cells
to
deliver
fluorescent
which
exhibited
pronounced
antiproliferative
activity
against
4T1
cancer
cells.
It
is
conceivable
that
this
could
find
applications
other
fields,
controlled
bond
cleavage
preferred.
Journal of Medicinal Chemistry,
Journal Year:
2024,
Volume and Issue:
67(12), P. 9789 - 9815
Published: June 12, 2024
Carbon
monoxide
(CO)
is
endogenously
produced
in
mammals,
with
blood
concentrations
the
high
micromolar
range
hemoglobin-bound
form.
Further,
CO
has
shown
therapeutic
effects
various
animal
models.
Despite
its
reputation
as
a
poisonous
gas
at
concentrations,
we
show
that
should
have
wide
enough
safety
margin
for
applications.
The
analysis
considers
large
number
of
factors
including
levels
endogenous
CO,
comparison
to
commonly
encountered
biomolecules
or
drugs,
anticipated
enhanced
profiles
when
delivered
via
noninhalation
mode,
and
amount
data
from
human
clinical
trials.
It
be
emphasized
having
use
does
not
mean
it
benign
safe
general
public,
even
low
doses.
We
defer
latter
public
health
experts.
Importantly,
this
Perspective
written
drug
discovery
professionals
public.
Journal of Materials Chemistry B,
Journal Year:
2023,
Volume and Issue:
11(9), P. 1849 - 1865
Published: Jan. 1, 2023
The
present
review
introduced
systematically
a
promising
strategy
for
cancer:
carbon
monoxide
therapy,
and
provided
some
valuable
guidance
promoting
the
progress
of
gas
therapy
nanomedicine.
Journal of Medicinal Chemistry,
Journal Year:
2023,
Volume and Issue:
66(21), P. 14583 - 14596
Published: Nov. 1, 2023
Carbon
monoxide
has
shown
promise
as
a
therapeutic
agent
against
cancers.
Reactive
oxygen
species
(ROS)-activated
CO
prodrugs
are
highly
demanded
for
targeted
cancer
treatment
but
remain
sporadic.
In
addition,
little
attention
is
on
how
the
release
rate
affects
CO's
biological
effects.
Herein,
we
describe
new
type
of
ROS-activated
metal-free
prodrug,
which
releases
with
tunable
rates
in
response
to
multiple
ROS
and
exhibits
very
pronounced
tumor
suppression
effects
mouse
4t1
breast
model.
Importantly,
first
time,
observe
both
vitro
vivo
that
direct
impact
its
antiproliferative
potency
correlation
between
activity
observed.
aggregates,
our
results
not
only
deliver
ROS-sensitive
also
represent
promising
starting
point
further
in-depth
studies
kinetics
affect
anticancer
activity.
Journal of the American Chemical Society,
Journal Year:
2022,
Volume and Issue:
145(1), P. 78 - 88
Published: Dec. 22, 2022
Extensive
studies
in
the
last
few
decades
have
led
to
establishment
of
CO
as
an
endogenous
signaling
molecule
and
subsequently
exploration
CO's
therapeutic
roles.
In
current
state,
there
is
a
critical
conundrum
CO-related
research:
extensive
knowledge
biological
effects
yet
insufficient
understanding
quantitative
correlations
between
concentration
responses
various
natures.
This
partially
due
difficulty
examining
precise
concentration–response
relationships
gaseous
molecule.
Another
reason
need
for
appropriate
tools
sensitive
detection
determination
system.
We
herein
report
new
chemical
approach
design
fluorescent
probes
through
de
novo
construction
fluorophores
by
insertion-initiated
lactamization
reaction,
which
allows
ultra-low
background
exclusivity
detection.
Two
series
been
designed
synthesized
using
this
strategy.
Using
these
probes,
we
extensively
demonstrated
their
utility
quantifying
blood,
tissue,
cell
culture
cellular
imaging
from
exogenous
sources.
The
described
will
enable
many
biology
chemistry
labs
study
functions
concentration-dependent
fashion
with
very
high
sensitivity
selectivity.
principles
also
be
applicable
designing
other
small
molecules.
Journal of Medicinal Chemistry,
Journal Year:
2023,
Volume and Issue:
66(24), P. 16546 - 16567
Published: Dec. 12, 2023
Time-
and
space-resolved
drug
delivery
is
highly
demanded
for
cancer
treatment,
which,
however,
can
barely
be
achieved
with
a
traditional
prodrug
strategy.
In
recent
years,
the
strategy
based
on
bioorthogonal
bond
cleavage
chemistry
has
emerged
advantages
of
high
temporospatial
resolution
over
activation
homogeneous
irrespective
individual
heterogeneity.
past
five
tremendous
progress
been
witnessed
in
this
field
one
such
entering
Phase
II
clinical
trials.
This
Perspective
aims
to
highlight
these
new
advances
(2019–2023)
critically
discuss
their
pros
cons.
addition,
remaining
challenges
potential
strategic
directions
future
will
also
included.
